Access

You are not currently logged in.

Access your personal account or get JSTOR access through your library or other institution:

login

Log in to your personal account or through your institution.

If You Use a Screen Reader

This content is available through Read Online (Free) program, which relies on page scans. Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.

(5Z,13E)-(15S)-9α ,11β ,15-trihydroxyprosta-5,13-dien-1-oic Acid (9α ,11β -prostaglandin F2): Formation and Metabolism by Human Lung and Contractile Effects on Human Bronchial Smooth Muscle

Karen Seibert, James R. Sheller and L. Jackson Roberts
Proceedings of the National Academy of Sciences of the United States of America
Vol. 84, No. 1 (Jan. 1, 1987), pp. 256-260
Stable URL: http://www.jstor.org/stable/28988
Page Count: 5
  • Read Online (Free)
  • Subscribe ($19.50)
  • Cite this Item
Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.
(5Z,13E)-(15S)-9α ,11β ,15-trihydroxyprosta-5,13-dien-1-oic Acid (9α ,11β -prostaglandin F2): Formation and Metabolism by Human Lung and Contractile Effects on Human Bronchial Smooth Muscle
Preview not available

Abstract

Prostaglandin D2 (PGD2) was recently found to be stereospecifically converted to the compound (5Z,13E)-(15S)-9α ,11β ,15-trihydroxyprosta-5,13-dien-1-oic acid (9α ,11β -PGF2) by a human liver cytosolic NADPH-dependent 11-ketoreductase enzyme. Because PGD2 is a potent bronchoconstrictor and is released into bronchoalveolar lavage fluid after allergen stimulation in patients with allergic asthma, the ability of human lung to metabolize PGD2 to 9α ,11β -PGF2 and the contractile effects of 9α ,11β -PGF2 on human bronchial smooth muscle were investigated. The 100,000 × g supernatant of human lung converted PGD2 in the presence of an NADPH-generating system stereospecifically to 9α ,11β -PGF2 at a rate of 3.46 ± 0.94 pmol per min per mg of protein. 9α ,11β -PGF2 was found to contract human bronchial rings in a dose-dependent fashion with a potency virtually identical with that of both PGD2 and PGF, known potent bronchial constrictors. PGD2 was found to be a very poor substrate for human lung 15-hydroxyprostaglandin dehydrogenases and to be preferentially metabolized by lung to 9α ,11β -PGF2· 9α ,11β -PGF2 was also found to be a very poor substrate for the lung 15-hydroxyprostaglandin dehydrogenases. Thus, once formed, 9α ,11β -PGF2 would not be expected to be rapidly inactivated in situ by these metabolic enzymes. These results suggest that 9α ,11β -PGF2 may participate along with other putative mediators in the pulmonary allergic response in humans.

Page Thumbnails

  • Thumbnail: Page 
256
    256
  • Thumbnail: Page 
257
    257
  • Thumbnail: Page 
258
    258
  • Thumbnail: Page 
259
    259
  • Thumbnail: Page 
260
    260